Combination Therapies Targeting Feedback Pathways Preclinical and early clinical data suggest that the co-targeting of EGFR or other receptor tyrosine kinases can overcome adaptive resistance to KRAS inhibition, particularly in CRC. The gene discussed is KRAS; the disease is colorectal carcinoma.